Stay updated on Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial
Sign up to get notified when there's something new on the Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial page.

Latest updates to the Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial page
- Check2 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe study details page now shows a 403 Forbidden error instead of the expected content. This blocks access to the NCT02530463 study details.SummaryDifference0.5%

- Check23 days agoChange DetectedThe study page now returns a 403 Forbidden error, blocking access to the study details. The additions include a 403 notice and a revision snippet (Revision: v3.7.0).SummaryDifference23%

- Check44 days agoChange DetectedThe page now shows Revision: v3.6.6, replacing the previous v3.6.5, indicating a new revision of the study record in the site footer.SummaryDifference0.0%

- Check65 days agoChange DetectedThe page now displays Revision: v3.6.5, replacing Revision: v3.6.4. This indicates a newer site version but does not imply changes to the study details presented on the page.SummaryDifference0.0%

- Check80 days agoChange DetectedThe page's revision tag was updated from v3.6.3 to v3.6.4, indicating a small update to the page's documentation or template.SummaryDifference0.0%

Stay in the know with updates to Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial page.